Literature DB >> 25550805

Inhibitory effects of intrathecal p38β antisense oligonucleotide on bone cancer pain in rats.

Hang Dong1, Hong-Bing Xiang2, Da-Wei Ye3, Xue-Bi Tian2.   

Abstract

OBJECTIVE: To evaluate the effects of intrathecal administration p38β antisense oligonucleotide on the development of bone cancer pain rats.
METHODS: Forty female SD rats weighing 180~220 g were randomly divided into 4 groups (n = 10 each): Group A (control group): intra-tibial injection of 3 μl Hank's solution; group B (model group): intra-tibial injection of 3 μl MADB-106 mammary gland carcinoma cells of rats (4.8 × 10(3)/μl); group C (p38β-SODN 20 μg); group D (p38β-ASODN 20 μg). The model procedures in group C and D were same to those in the group B. From the 14th day after operation, p38β-SODN 20 μg and p38β-ASODN 20 μg were respectively intrathecally administrated in group C and D once daily for 6 days whereas normal saline was for group A and B. Mechanical withdrawal threshold and radiant heat threshold of rat hind paws were measured before operation and every other day until 22 d of post-operation. The lumbar 4-6 spinal cord was removed on the 22(nd) day. The expression of spinal p38β protein was determined by Western blot.
RESULTS: No significant differences in mechanical withdrawal threshold and radiant heat threshold were found at all time points in control group. During the first 6 days after operation there were obvious differences in radiant heat stimulus between control group between the other groups (P < 0.05); During 14-22 days after operation, mechanical pain threshold and radiant heat threshold between p38β-SODN group and Model group were significantly changed compared with that in control group (P < 0.05). However, the differences were not remarkable between control group and p38β-ASODN group (P > 0.05). The expression of p38β protein in lumbar spinal cord was significantly higher between p38β-SODN group and Model group than that in control group (P < 0.05). There was no significant difference in p38β protein expression between p38β-ASODN group and control group (P > 0.05).
CONCLUSIONS: Hyperalgesia induced by bone cancer can be inhibited by intrathecal administration of p38β antisense oligonucleotide, which is achieved by reducing expression of p38β protein.

Entities:  

Keywords:  Bone cancer pain; antisense oligonucleotides; hyperalgesia; p38beta; spinal dorsal horn

Mesh:

Substances:

Year:  2014        PMID: 25550805      PMCID: PMC4270575     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  42 in total

1.  A method for increasing the viability of the external portion of lumbar catheters placed in the spinal subarachnoid space of rats.

Authors:  E D Milligan; J L Hinde; K K Mehmert; S F Maier; L R Watkins
Journal:  J Neurosci Methods       Date:  1999-08-01       Impact factor: 2.390

2.  [The cellular location and significance of p38alpha/beta isoforms in the lumbar spinal cord of the bone cancer pain rats].

Authors:  Hang Dong; Yu-Ke Tian; Hong-Bing Xiang; Xue-Bi Tian; Xiao-Gao Jin
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2007-01-02

3.  Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain.

Authors:  Tansy Donovan-Rodriguez; Anthony H Dickenson; Catherine E Urch
Journal:  Anesthesiology       Date:  2005-01       Impact factor: 7.892

Review 4.  Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.

Authors:  Chuanbo Zhang; Jin Pei; Deepak Kumar; Isamu Sakabe; Howard E Boudreau; Prafulla C Gokhale; Usha N Kasid
Journal:  Methods Mol Biol       Date:  2007

5.  Intrathecal minocycline attenuates peripheral inflammation-induced hyperalgesia by inhibiting p38 MAPK in spinal microglia.

Authors:  Xiao-Ying Hua; Camilla I Svensson; Tomohiro Matsui; Bethany Fitzsimmons; Tony L Yaksh; Michael Webb
Journal:  Eur J Neurosci       Date:  2005-11       Impact factor: 3.386

6.  Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis.

Authors:  Tomoyuki Inoue; David L Boyle; Maripat Corr; Deepa Hammaker; Roger J Davis; Richard A Flavell; Gary S Firestein
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

7.  Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.

Authors:  Gabriel Mbalaviele; Gary Anderson; Amy Jones; Pamela De Ciechi; Steve Settle; Steve Mnich; Mark Thiede; Yousef Abu-Amer; Joseph Portanova; Joseph Monahan
Journal:  J Pharmacol Exp Ther       Date:  2006-02-24       Impact factor: 4.030

8.  Generation and characterization of p38beta (MAPK11) gene-targeted mice.

Authors:  Victoria A Beardmore; Heather J Hinton; Christina Eftychi; Maria Apostolaki; Maria Armaka; Joanne Darragh; Joanne McIlrath; Julia M Carr; Laura J Armit; Carol Clacher; Loraine Malone; George Kollias; J Simon C Arthur
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

9.  MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis.

Authors:  Martin Hegen; Matthias Gaestel; Cheryl L Nickerson-Nutter; Lih-Ling Lin; Jean-Baptiste Telliez
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

10.  Regulation of peripheral inflammation by spinal p38 MAP kinase in rats.

Authors:  David L Boyle; Toni L Jones; Deepa Hammaker; Camille I Svensson; Sanna Rosengren; Salvatore Albani; Linda Sorkin; Gary S Firestein
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

View more
  2 in total

1.  Intrathecal administration of antisense oligonucleotide against p38α but not p38β MAP kinase isoform reduces neuropathic and postoperative pain and TLR4-induced pain in male mice.

Authors:  Xin Luo; Bethany Fitzsimmons; Apoorva Mohan; Linlin Zhang; Niccolo Terrando; Holly Kordasiewicz; Ru-Rong Ji
Journal:  Brain Behav Immun       Date:  2017-11-08       Impact factor: 7.217

Review 2.  p38β and Cancer: The Beginning of the Road.

Authors:  Olga Roche; Diego M Fernández-Aroca; Elena Arconada-Luque; Natalia García-Flores; Liliana F Mellor; María José Ruiz-Hidalgo; Ricardo Sánchez-Prieto
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.